SCHEDULE 13G/A: Avoro Capital Advisors and Behzad Aghazadeh Disclose 4.2% Stake in BioCryst Pharmaceuticals

Avoro Capital Advisors LLC and its controlling person, Behzad Aghazadeh, have disclosed a beneficial ownership of 4.2% in BioCryst Pharmaceuticals Inc., totaling 8.7 million shares.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh, its portfolio manager and controlling person, have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses their beneficial ownership of 8,700,000 shares of Common Stock in BioCryst Pharmaceuticals Inc.
• This ownership represents 4.2% of BioCryst Pharmaceuticals' outstanding Common Stock.
• The percentage is calculated based on 208,960,020 shares of Common Stock outstanding as of February 20, 2025, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024.
• Both Avoro Capital Advisors LLC and Behzad Aghazadeh hold sole voting and sole dispositive power over these 8.7 million shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm can be viewed positively by the market, suggesting confidence in the company. However, the document itself is a factual filing and does not contain operational or financial news that would significantly sway sentiment beyond this.

Positives

• A significant institutional investor and its principal have taken a notable stake in BioCryst Pharmaceuticals, potentially signaling confidence in the company's long-term prospects.

Negatives

• The document does not contain any negative information regarding the company's operations or financial performance, as it is a beneficial ownership disclosure.

Risks

• The document itself does not detail specific risks related to BioCryst Pharmaceuticals' operations or financial health, as its purpose is to disclose beneficial ownership.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding BioCryst Pharmaceuticals' future performance or strategic direction, as it is solely a beneficial ownership disclosure.

Industry Context

This filing indicates a significant stake taken by an investment advisor specializing in life sciences, Avoro Capital Advisors, in a pharmaceutical company. Such disclosures are common in the biotechnology and pharmaceutical sectors, where institutional investors often take positions based on perceived drug development potential or market opportunities.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be perceived as a vote of confidence, potentially influencing investor sentiment and share price.

Key Dates

Keywords

BioCryst Pharmaceuticals, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology, SEC Filing